Chronic cholestatic diseases

Journal of Hepatology

Volumn 32, Issue SUPPL.1, 2000, Pages 129-140

  Poupon, R ^a   Chazouilleres O ^a   Poupon, R E ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSERM   (France)

Author keywords

Bile acids; Cholestatis; Overlap syndrome; Primary biliary cirrhosis; Primary sclerosing cholangitis; Progressive familial intrahepatic cholestasis; Ursodeoxycholic acid

Indexed keywords

URSODEOXYCHOLIC ACID;

ALAGILLE SYNDROME; AUTOIMMUNE DISEASE; BILE ACID SYNTHESIS; BILE DUCT ATRESIA; BILE DUCT CARCINOMA; BILE SECRETION; CHOLANGIOGRAPHY; CHOLESTASIS; GENETIC DISORDER; HUMAN; LIVER BIOPSY; LIVER TRANSPLANTATION; PORTOENTEROSTOMY; POSITRON EMISSION TOMOGRAPHY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW;

ADULT; ANTI-INFLAMMATORY AGENTS; CHILD, PRESCHOOL; CHOLAGOGUES AND CHOLERETICS; CHOLESTASIS; CHRONIC DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; URSODEOXYCHOLIC ACID;

EID: 0034006662     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(00)80421-3     Document Type: Article

References (120)

1. Desmet VJ. Congenital diseases of intrahepatic bile ducts: variation on the theme "Ductal plate malformation". Hepatology 1992; 16: 1069-83.
2. Balistreri WF, Grand R, Suchy FJ, Ryckman FC, Perlmutter DH, Sokol RJ. Biliary atresia: current concepts and research directions. Summary of a symposium. Hepatology 1996; 23: 1682-97.
3. Otte JB, de Ville de Goyet J, Reding R, Hausleithner V, Sokal E, Chardot C, et al. Sequential treatment of biliary atresia with Kasai portoenterostomy and liver transplantation: a review. Hepatology 1994; 20: 41S-8S.
4. Alagille D, Odievre M, Gautier M, Dommergues JP. Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental, and sexual development, and cardiac murmur. J Pediatr 1976; 86: 63-71.
5. Deleuze JF, Dhorne-Pollet S, Pollet N, Meunier-Rotival M, Hadchouel M. Le syndrome d'Alagille en 1995. Données cliniques et génétiques. Gastroenterol Clin Biol 1995; 19: 587-96.
6. Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology 1999; 29: 822-9.
7. Oda T, Elkahloun AG, Pike BL, Okajima K, Krantz ID, Genin A, et al. Mutations in the human jagged1 gene are responsible for Alagille syndrome. Nat Genet 1997; 16: 235-42.
8. Li L, Krantz ID, Deng Y, Genin A, Banta AB, Collins CC, et al. Alagille syndrome is caused by mutations in human jagged1, which encodes a ligand for notch1. Nat Genet 1997; 16: 243-51.
9. Krantz ID, Colliton RP, Genin A, Rand EB, Li L, Piccoli DA, et al. Spectrum and frequency of jagged1 (JAG1) mutations in Alagille syndrome patients and their families. Am J Hum Genet 1998; 62: 1361-9.
10. Crosnier C, Driancourt C, Raynaud N, Dhorne-Pollet S, Pollet N, Bernard O, et al. Mutations in jagged1 gene are predominantly sporadic in Alagille syndrome. Gastroenterology 1999; 116: 1141-8.
11. Jacquemin E, Hadchouel M. Genetic basis of progressive familial intrahepatic cholestasis. J Hepatol 1999; 31: 377-81.
12. Bull LN, van Eijk MJ, Pawlikowska L, DeYoung JA, Juijn JA, Liao M, et al. A gene encoding a p-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet 1998; 18: 219-24.
13. Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998; 20: 233-8.
14. Jacquemin E, Hermans D, Myara A, Habes D, Debray D, Hadchouel M, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997; 25: 519-23.
15. Ruetz S, Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 1994; 77: 1071-81.
16. Deleuze JF, Jacquemin E, Dubuisson C, Cresteil D, Dumont M, Erlinger S, et al. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology 1996; 23: 904-8.
17. De Vree JM, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci U SA 1998; 95: 282-7.
18. Van Nieuwkerk CJM, Oude Elferink RPJ, Groen AK, Ottenhoff R, Tytgat GNJ, Dingemans KP, et al. Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 p-glycoprotein gene. Gastroenterology 1996; 111: 165-71.
19. Setchell KDR. Disorders of bile acid synthesis and metabolism. In: Walker WA, Durie PR, Hamilton JR, Walker-Smith JA, Watkins JA, eds. Pediatric gastrointestinal disease. Pathophysiology, diagnosis, management. Toronto/Philadelphia: B C Decker Inc, 1996; 1205-33.
20. Clayton PT, Leonard JV, Lawson AM, Setchell KDR, Andersson S, Egestad B, et al. Familial giant cell hepatitis associated with synthesis of 3β, 7α-dihydroxy- and 3β, 7α, 12α-trihydroxy-5-cholenoic acids. J Clin Invest 1987; 79: 1031-8.
21. Setchell KDR, Suchy FJ, Welsh MB, Zimmer-Nechemias L, Heubi J, Balistreri WF. Δ4-3-oxosteroid 5β-reductase deficiency described in identical twins with neonatal hepatitis. A new inborn error in bile acid synthesis. J Clin Invest 1988; 82: 2148-57.
22. Clayton PT, Casteels M, Mieli-Vergani G, Lawson AM. Familial giant cell hepatitis with low bile acid concentrations and increased urinary excretion of specific bile alcohols: a new inborn error of bile acid synthesis? Pediatr Res 1995; 37: 424-31.
23. Setchell KDR, Schwarz M, O'Connel NC, Lund EG, Davis DL, Lathe R, et al. Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7α-hydroxylase gene causes severe neonatal liver disease. J Clin Invest 1998; 102: 1690-703.
24. Bandin O, Courvalin J, Poupon R, Dubel L, Homberg J, Johannet C. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypepticle in the diagnosis of primary biliary cirrhosis. Hepatology 1996; 23: 1020-4.
25. Wesierska-Gadek J, Honenauer H, Hitchman E, Penner E. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology 1996; 110: 840-7.
26. Züchner D, Sternsdorf T, Szostecki C, Heathcote JE, Cauch-Dudek K, Will H. Prevalence, kinetics and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology 1997; 26: 1123-30.
27. Michieletti P, Wanless IR, Katz A, Scheuer PJ, Yeaman SJ, Bassendine MF, et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut 1994; 35: 260-5.
28. Taylor SL, Dean PJ, Riely CA. Primary autoimmune cholangitis. An alternative to antimitochondrial antibody-negative primary biliary cirrhosis. Am J Surg Pathol 1994; 18: 91-9.
29. Goodman ZD, MacNally PR, Davis DR, Ishak KG. Autoimmune cholangitis: a variant of primary biliary cirrhosis. Clinicopathologic and serologic correlations in 200 cases. Dig Dis Sci 1995; 40: 1232-42.
30. Gordon SC, Quattrociocchi-Longe TM, Khan BA, Kodali VP, Chen J, Silverman AL, et al. Antibodies to carbonic anhydrase in patients with immune cholangiopathies. Gastroenterology 1995; 108: 1802-9.
31. Invernizzi P, Battezzati PM, Crosignani A, Zermiani P, Bignotto M, del Papa N, et al. Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status. Clin Exp Immunol 1998; 114: 448-54.
32. Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997; 25: 1090-5.
33. Kim WR, Poterucha JJ, Jorgensen RA, Batts KR Homburger HA, Dickson ER, et al. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology 1997; 26: 22-6.
34. Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296-301.
35. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disase. Hepatology 1998; 28: 360-5.
36. Colombato LA, Alvarez F, Cote J, Huet PM. Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis? Gastroenterology 1994; 107: 1839-43.
37. Degott C, Zafrani ES, Callard P, Balkau B, Poupon RE, Poupon R. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 1999; 20: 1007-12.
38. Lohse AW, Meyer zum Büschenfelde KH, Franz B, Kanzler S, Gerken G, Dienes GP. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999; 29: 1078-84.
39. Van de Water J, Fregeau D, Davis P, Ansari AA, Danner D, Leung R et al. Autoantibodies of primary biliary cirrhosis recognixe dihydrolipoamide acyltransferase and inhibit enzyme function. J Immunol 1988; 141: 2321-4.
40. Yeaman SJ, Fussey SPM. Danner DJ, James OFW, Mutimer DJ, Bassendine MF. Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1988; 1: 1067-70.
41. Jones DE, Palmer J, Yeaman S, James O, Bassendine M, Diamond AG. T-cell responses to components of pyruvate dehydrogenase complex in primary biliary cirrhosis. Hepatology 1995; 21: 995-1002.
42. Coutinho A, Kazatchkine MD. Autoimmunity. Physiology and disease, Edn. New York: John Wiley and Sons, 1994.
43. Van de Water J, Turchany J, Leung PSC, Lake J, Munoz S, Surth CD, et al. Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest 1993; 91: 2653-64.
44. Joplin RE, Wallace LL, Lindsay JG, Palmer JM, Yeaman SJ, Neuberger JM. The human biliary epithelial cell plasma membrane antigen in primary biliary cirrhosis: pyruvate dehydrogenase X. Gastroenterology 1997; 113: 1727-33.
45. Sadamato T, Joplin R, Keogh A, Mason A, Carman W, Neuberger J. Expression of pyruvate-dehydrogenase complex PDC-E2 on biliary epithelial cells induced by lymph nodes from primary biliary cirrhosis. Lancet 1998; 352: 1595-6.
46. Harada K, van de Water J, Leung PSC, Coppel RL, Nakanuma Y, Gershwin ME. In situ nucleic acid hybridization of pyruvate dehydrogenase complex-E2 in primary biliary cirrhosis: pyruvate dehydrogenase complex-E2 messenger RNA is expressed in hepatocytes but not in biliary epithelium. Hepatology 1997; 25: 27-32.
47. Harada K, Sudo Y, Kono N, Ozaki S, Tsuneyama K, Gershwin ME, et al. In situ nucleic acid detection of PDC-E2, BCOADS-E2, OGDC-E2, PDC-ELα, BCOADC-ELα, OGDC-E1, and the E3 binding protein (protein X) in primary biliary cirrhosis. Hepatology 1999; 30: 36-45.
48. Spengler U, Möller A, Jung MC, Messer G, Zachova R, Hoffmann RM, et al. T lympocytes from patients with primary biliary cirrhosis produce reduced amounts of lymphotoxin, tumor necrosis factor and interferon-y upon mitogen stimulation. J Hepatol 1992; 15: 129-35.
49. Larrea E, Garcia N, Qian C, Civeira MP, Prieto J. Enhanced expression of TNF in patients with primary biliary cirrhosis. Int Hepatol Comm 1994; 2: 6-13.
50. Harada K, van de Water J, Leung PSC, Coppel RL, Ansari A, Nakanuma Y, et al. In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset. Hepatology 1997; 25: 791-6.
51. Krams SM, Cao S, Hayashi M, Villanueva JC, Martinez OM. Elevations in IFN-γ, IL-5, IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. Clin Immunol Immunopathol 1996; 80: 311-20.
52. Yamashiki M, Kosaka. Y, Nishimura A, Watanabe S, Nomoto M, Ichida F. Analysis of serum cytokine levels in primary biliary cirrhosis patients and healthy adults. J Clin Lab Anal 1998; 12: 77-82.
53. Kakimoto K, Katsuki M, Hirofuji T, Itawa H, Koga T. Isolation of T cell line capable of protecting mice against colagen-induced arthritis. J Immunol 1988; 140: 78.
54. Miller KB, Sepersky RA, Brown KM, Goldberg MJ, Kaplan MM. Genetic abnormalities of immunoregulation in primary biliary cirrhosis. Am J Med 1983; 75: 75-80.
55. Bach N, Schaffner F. Familial primary biliary cirrhosis. J Hepatol 1994; 20: 698-701.
56. Donaldson P, Doherty D, Underhill J, Williams R. The molecular genetics of autoimmune liver disease. Hepatology 1994; 20: 226-39.
57. Gregory WL, Bassendine MF. Genetic factors in primary biliary cirrhosis. J Hepatol 1994; 20: 689-92.
58. Manns MP, Krüger M. Immunogenetics of chronic liver diseases. Gastroenterology 1994; 106: 1676-97.
59. Gregory WL, Daly AK, Dunn AN, Cavanagh G, Idle JR, James OFW, et al. Analysis of HLA-class-II-encoded antigen-processing genes TAP1 and TAP2 in primary biliary cirrhosis. Q J Med 1994; 87: 237-44.
60. Manns MP, Bremm A, Schneider PM, Notghi A, Gerken G, Prager-Eberle M, et al. HLA DRw 8 and complement C4 deficiency as risk factor in primary biliary cirrhosis. Gastroenterology 1991; 101: 1367-73.
61. Ficher A, Rieux-Laucat F, Le Deist F. A new peak in the ALPS. Nature Med 1999; 5: 876-7.
62. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884-90.
63. Poupon RE, Bonnand A-M, Chretien Y, Poupon R, and the UDCA-PBC Study Group. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Hepatology 1999; 29: 1668-71.
64. Angulo P, Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Kamath PS, et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999; 19: 115-21.
65. Lindor KD, Jorgensen RA, Therneau TM, Malinchoc M, Dickson ER. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997; 72: 1137-40.
66. Bonnand A-M, Heathcote EJ, Lindor KD, Poupon RE. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 1999; 29: 39-43.
67. Poupon RE, Balkau B, Eschwège E, Poupon R, and the UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324: 1548-54.
68. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh P, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284-90.
69. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19: 1149-56.
70. Angulo P, Dickson ER, Therneau TM, Jorgensen RA, Smith C, DeSotel CK, et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999; 30: 830-5.
71. van Hoogstraten HJF, de Smet MBM, Renooij W, Breed JGS, Engels LGJB, den Ouden-Muller JW, et al. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10/mg/kg or 20 mg/kg. Aliment Pharmacol Ther 1998; 12: 965-71.
72. Holsti P. Experimental cirrhosis of the liver in rabbits induced by gastric instillation of dessicated whole bile. Acta Pathol Microbiol Scand 1956; 112: 1-67.
73. Holsti P. Cirrhosis of the liver induced in rabbits by gastric instillation of 3-monohydroxycholanic acid. Nature 1960; 186: 250.
74. Kitani K, Kanai S. Tauroursodeoxycholate prevents taurocholate induced cholestasis. Life Sci 1982; 30: 516-23.
75. Kitani K. Hepatoprotective effect of ursodeoxycholate in experimental animals. In: Paumgartner G, Stiehl A, Barbara L, Roda E, et al., editors. Strategies for the Treatment of Hepato-biliary Diseases. Dordrecht: Kluwer; 1990. p. 43-56.
76. Poupon R, Chrétien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1: 834-6.
77. Heuman DM, Mills AS, MacCall J, Hylemon PB, Pandak WM, Vlahcevic ZR. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts - In vivo studies in the rat. Gastroenterology 1991; 1: 203-11.
78. Jazrawi RP, De Caestecker JS, Goggin PM, Britten AJ, Joseph AK, Maxwell JD, et al. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994; 106: 134-42.
79. Marteau P, Chazouillères O, Myara A, Jian R, Rambaud JC, Poupon R. Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man. Hepatology 1990; 12: 1206-8.
80. Stiehl A, Raedsch R, Rudolph G. Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids. Gastroenterology 1990; 98: 424-8.
81. Poupon RE, Chrétien Y, Poupon R, Paumgartner G. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 1993; 17: 599-604.
82. Häussinger D, Saha N, Hallbrucker C, Lang F, Gerok W. Involvement of microtubules in the swelling-induced stimulation of transcellular taurocholate transport in perfused rat liver. Biochem J 1993; 291: 355-60.
83. Schliess F, Kurz AK, vom Dahl S, Häussinger D. Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver. Gastroenterology 1997; 113: 1306-14.
84. Beuers U, Throckmorton DC, Anderson MS, Isales CM, Thasler W, Kullak-Ublick G-A, et al. Tauroursodeoxycholic acid activates protein kinase C in isolated hepatocytes. Gastroenterology 1996; 110: 1553-63.
85. Güldütuna S, Immer G, Imohof B, S, You T, Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology 1993; 104: 1736-44.
86. Zhang F, Subbaramaiah K, Altorki N, Dannenberg AJ. Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J Biol Chem 1998; 273: 2424-8.
87. Vishwanath BS, Frey FJ, Escher G, Reichen J, Frey BM. Liver cirrhosis induces renal and liver phospholipase A2 activity in rats. J Clin Invest 1996; 98: 365-71.
88. Hillaire S, Boucher E, Calmus Y, Gane P, Ballet F, Franco D, et al. Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterology 1994; 107: 781-8.
89. Invernezzi P, Salzman AL, Czabo C, Ueta I, O'Connor M, Setchell KDR. Ursodeoxycholate inhibits induction of NOS in human intestinal epithelial cells and in vivo. Am J Physiol 1997; 273: G131-G8.
90. Tanaka H, Makino Y, Miura T, Hirano F, Okamoto K, Komura K, et al. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-γ-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway. J Immunol 1996; 156: 1601-8.
91. Sasatomi K, Noguchi K, Sakisaka S, Sata M, Tanikawa K. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 1998; 29: 409-16.
92. Ide T, Sata M, Nakano H, Suzuki H, Tanikawa K. Increased serum IgM class anti-lipid A antibody and therapeutic effect of ursodeoxycholic acid in primary biliary cirrhosis. Hepatogastroenterology 1997; 44: 1569-73.
93. Botla R, Spivey JR, Aguilar H, Bronk SF, Gores GJ. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA protection. J Pharmacol Exp Ther 1995; 272: 930-8.
94. Rodrigues CMR Guangsheng F, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998; 101: 2790-9.
95. Rodrigues CMP, Fan G, Wong PY, Kren BT. Steer CJ. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 1998; 4: 165-78.
96. Koga H, Sakisaka S, Ohishi M, Sata M, Tanikawa K. Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology 1997; 25: 1077-84.
97. Yamazaki K, Suzuki K, Nakamura A, Sato S, Lindor KD, Batts KP, et al. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Hepatology 1999; 30: 71-8.
98. Medina JF, Martínez-Ansó E, Vázquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 1997; 25: 12-7.
99. Poupon RE, Poupon R. Ursodeoxycholic acid for primary biliary cirrhosis. In: Boyer JL, Jansen PLM, Manns MP, Reichen J, editors. Cholestatic Liver Diseases. Dordrecht: Kluwer Academic; 1998. p. 271-7.
100. Leuschner U, Maier KP, Güldütuna S, Parté-Peterhans S, Leuschner M. Ursodeoxycholic acid in combination with prednisolone or budenoside in the therapy of primary biliary cirrhosis. In: Paumgartner G, Stiehl A, Gerok W, editors. Bile Acids in Hepatobiliary diseases. Basic Research and Clinical Application. Dordrecht: Kluwer Academic Publishers; 1997. p. 299-302.
101. Lichtman SN, Keku J, Clark RL, Schwab JH, Sartor RB. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology 1991; 13: 766-72.
102. Le Thi Huong D, Valla D, Franco D, Wechsler B, De Gramont A, Auperin A, et al. Cholangitis associated with paroxysmal nocturnal hemoglobinuria: another instance of ischemic cholangiopathy? Gastroenterology 1995; 109: 1338-43.
103. Washington K, Clavien PA, Killenberg P. Peribiliary vascular plexus in primary sclerosing cholangitis and primary biliary cirrhosis. Human Pathol 1997; 28: 791-5.
104. Mehal WZ, Lo Y-MD, Wordsworth BP, Neuberger JM, Hubscher SC, Fleming KA, et al. HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1994; 106: 160-7.
105. Das KM, Vecchi M, Sakamaki S. A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology 1990; 98: 464-9.
106. Gohlke F, Lohae AW, Dienes HP, Lohr H, Marker-Hermann E, Gerken G, et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 1996; 24: 699-705.
107. Boberg KM, Fausa O, Haaland T, Holter E, Mellebye OJ, Spurkland A, et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996; 23: 1369-76.
108. Broome U, Olsson R, Loof L, Bodemar B, Hultcrantz R, Danielsson A, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610-5.
109. Li-Yeng C, Goldberg HI. Sclerosing cholangitis: broad spectrum of radiographic features. Gastrointest Radiol 1984; 9: 39-47.
110. Ludwig J. Small-duct primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 11-7.
111. Wee A, Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? Ann Intern Med 1985; 102: 581-7.
112. Pasha TM, Petz J, Ludwig J, Therneau TM, Benson JT, Malinchoc M, et al. Incidence of cholangiocarcinoma in patients with primary sclerosing cholangitis. Hepatology 1997; 26: 170A.
113. Hulcrantz R, Olsson R, Danielsson A, Jarnerot G, Loof L, Ryden BO, et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 1999; 30: 669-73.
114. Brentnall TA, Haggit RC, Rabinovitch PS, Kimmery MB, Bronner MP. Levine DS, et al. Risk and natural history of coIonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996; 110: 331-8.
115. Stiehl A, Rudolph G, Sauer P, Benz C, Stremmel W S W et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. J Hepatol 1997; 26: 560-6.
116. Lindor KD, for the Mayo Primary Sclerosing-Ursodeoxycholic Acid Study Group. Ursodiol for primary sclerosing chongitis. N Engl J Med 1997; 336: 691-5.
117. Abu-Elmagd K, Malinchoc M, Dickson ER, Fung JJ, Murtaugh PA, Langworthy AL, et al. Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis. Surg Gynecol Obstet 1993; 177: 336-44.
118. Consensus statement on indications for liver transplantation: Paris, June 2223, 1993. Hepatology 1994; 20: 63S-8S.
119. Loftus EV, Aguilar HI, Sandborn WJ, Tremaine WJ. Krom RAF, Zinsmeister AR, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology. 1998: 27: 685-90.
120. Graziadei IW, Wiesner RH, Batts KP, Marotta PJ, Larusso NF, Porayko MK, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999; 29: 1050-6.